Tag: 2023

Combining High-Throughput, High-Resolution Targeted Spatial Microdissection with SLIMamp® NGS Chemistry for Sensitive and Accurate Molecular Characterization on Low-Quantity, Low-Quality FFPE Samples

Pillar, QuantumCyte and AstraZeneca tested whether AI-guided spatial microdissection can rescue FFPE samples that would otherwise fail NGS. QuantumCyte’s QCPRECISE!™ platform uses digital pathology to annotate slides and a printed mask to remove unwanted regions, extracting DNA from selectively lysed tumor cells in 2 mm tissue microarray cores taken from 31 samples previously characterized on Pillar’s oncoReveal® HRD and BRCA1 & RAD51C methylation panels. Libraries were sequenced on the NextSeq 550 and analyzed in PiVAT®. Variants were called on all 31 samples with no cross-contamination, and 76% of evaluable samples matched known variant allele frequencies at 0.93 correlation.

Evaluation of Homologous Repair Deficiency Status in Ovarian Carcinoma using In House Next Generation Sequencing Panels

Temple University Hospital evaluated Pillar’s oncoReveal® HRDv2 assay together with the oncoReveal® methylation assay for assessing homologous recombination deficiency (HRD) in ovarian carcinoma, the marker predicting PARP inhibitor benefit in tubo-ovarian high-grade serous carcinoma. Thirty-one retrospective FFPE ovarian specimens — 20 high-grade serous, 4 clear cell, 3 mucinous, 3 endometrioid and 1 mixed — were microdissected and run for SNVs, indels and exon-level copy number variants across 33 genes on the Illumina MiSeq, plus BRCA1, BRCA2, RAD51C and XRCC3 promoter methylation, with PiVAT® analysis. Pathogenic HRD mutations appeared in 28 of 31 specimens (90%), and methylation identified further HRD-positive cases.

Pillar Biosciences Launches oncoReveal Core LBx, an NGS Kit to Enable Localized Liquid Biopsy-Based Tumor Profiling

Research Use Only (RUO) NGS Kit will provide a simple, automatable, industry-leading liquid biopsy workflow NATICK, Mass. – September 19, 2023 – (PR NEWSWIRE) – Pillar Biosciences, Inc., the leader in Decision Medicine™, has announced the global launch of oncoReveal™ Core LBx, a research-use-only (RUO) next-generation sequencing (NGS) kit that will provide the foundation for laboratories […]

Illumina and Pillar Biosciences Partner to Improve Access to Personalized Cancer Treatment Options

SAN DIEGO, JULY 25, 2023 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Pillar Biosciences Inc., the pioneers of Decision Medicine™, today announced a strategic partnership to make Pillar’s suite of oncology assays commercially available globally as part of the Illumina portfolio of oncology products. The agreement […]

Pillar Biosciences and KeyGene Enter into Licensing Agreement

NATICK, Mass. and WAGENINGEN, Netherlands, April 13, 2023 /PRNewswire/ — Pillar Biosciences, Inc., the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) tests to localize testing and reduce time to treatment initiation and testing costs, today announced a non-exclusive licensing agreement with Keygene N.V. related to their patent family entitled Combinatorial sequence barcodes for high throughput screeningfor use in Pillar […]

Pillar Biosciences Receives College of American Pathologists (CAP) Accreditation

NATICK, Mass.–(BUSINESS WIRE)–Pillar Biosciences, Inc., the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) tests to localize testing and reduce time to treatment initiation and testing costs, today announced their receipt of the College of American Pathologists (CAP) Accreditation for its CLIA certified reference lab. As one of the most rigorous laboratory certifications, the […]